For all queries call: +1.732.777.1111 | info@sabinsa.com
ForsLean®
  • ForsLean®
    • Overview
    • Chemistry
    • Mechanism of Action
    • Sustainability
  • Research
    • Clinical Studies
      • INDIA
      • JAPAN
      • USA
    • Safety Aspects
  • IP Rights
  • Achievements
  • Newsroom
    • Press Releases
    • Newsletters
    • White Papers
    • Articles
    • Videos
    • AD’s
    • FAQ
  • About Sabinsa
  • Contact Us

Press Releases

Latest Press Releases
March 30, 2001 Big

ForsLean addresses overall metabolic health and not just weight management, says Mr. Shaheen Majeed, President-Worldwide, Sabinsa

May 2, 2019
At April’s SupplySide East trade show, Sabinsa Corp. (East Windsor, NJ) explained how its branded Coleus forskohlii extract ingredient, ForsLean, is approaching the weight management.
Read more
ForsLean

Sabinsa Awarded New Patents For ForsLean®: New Scientific Discoveries Warrant Energy Balance Claims

April 4, 2019
Sabinsa announces that it has been awarded Japanese Patent Number 6472453, US Patent Number 10085963, and Australian Patent Number 2015351423, entitled “Process and compositions for.
Read more
coleus forskohlii

Sabinsa Publishes ForsLean® Safety Data in International Journal of Pharmacy & Pharmaceutical Research

January 19, 2016
Sabinsa Corporation and Sami Labs founder Dr. Muhammed Majeed was lead author of a paper published on the cumulative safety data of ForsLean®, the company’s.
Read more
Press Releases
March 30, 2001 Big

ForsLean addresses overall metabolic health and not just weight management, says Mr. Shaheen Majeed, President-Worldwide, Sabinsa

  • May 2, 2019
  • .Press Releases
  • .0 Comments
At April’s SupplySide East trade show, Sabinsa Corp. (East Windsor, NJ) explained how its branded Coleus forskohlii extract ingredient, ForsLean, is approachi...
Read More
Posted by forslean
  • Share
  • Tweet
ForsLean

Sabinsa Awarded New Patents For ForsLean®: New Scientific Discoveries Warrant Energy Balance Claims

  • April 4, 2019
  • .Press Releases
  • .0 Comments
Sabinsa announces that it has been awarded Japanese Patent Number 6472453, US Patent Number 10085963, and Australian Patent Number 2015351423, entitled “Proce...
Read More
Posted by forslean
  • Share
  • Tweet
coleus forskohlii

Sabinsa Publishes ForsLean® Safety Data in International Journal of Pharmacy & Pharmaceutical Research

  • January 19, 2016
  • .Press Releases
  • .0 Comments
Sabinsa Corporation and Sami Labs founder Dr. Muhammed Majeed was lead author of a paper published on the cumulative safety data of ForsLean®, the company’s ...
Read More
Posted by forslean
  • Share
  • Tweet
ForsLean® Soft Extracts

Sabinsa Introduces Softgel Ready ForsLean® Soft Extracts Amid Exponential Growth In Coleus Demand: Company Cautions Against Low Quality Spam Knockoffs

  • July 8, 2014
  • .Press Releases
  • .0 Comments
Just in time for legitimate dietary supplement manufacturers to differentiate their products from the inferior spamtouted forskolin products driven by Dr. Oz an...
Read More
Posted by forslean
  • Share
  • Tweet
Coleus forskohlii extract

Sabinsa Receives Payment from Creative Compounds for ForsLean® Trademark Infringement

  • July 10, 2012
  • .Press Releases
  • .0 Comments
An intellectual property battle lasting three years and reaching the US Supreme Court has ended at last with payment to Sabinsa Corporation by Creative Compound...
Read More
Posted by forslean
  • Share
  • Tweet
source of forskolin

Creative Compounds’ Attempt to Continue Trademark Infringement of Sabinsa’s ForsLean® Rejected by US Supreme Court

  • February 9, 2011
  • .Press Releases
  • .0 Comments
Sabinsa’s International Presence Sabinsa Corporation’s protracted battle against Creative Compounds’ trade mark infringement of Sabinsa’...
Read More
Posted by forslean
  • Share
  • Tweet
Sabinsa Granted Forskolin Solubility Patent In China

Sabinsa Granted Forskolin Solubility Patent In China

  • December 15, 2010
  • .Press Releases
  • .0 Comments
Sabinsa’s International Presence The State Intellectual Property Office of the People’s Republic of China has granted Sabinsa a patent entitled: ...
Read More
Posted by forslean
  • Share
  • Tweet
Newsroom-16

Sabinsa’s ForsLean® Gets PI Numbers From TGA To Enter Australian Market

  • July 12, 2010
  • .Press Releases
  • .0 Comments
Sabinsa Corporation has received Product Information (PI) numbers for ForsLean® 10% and 20% from Australia’s TGA (Therapeutic Goods Administration), a divisi...
Read More
Posted by forslean
  • Share
  • Tweet
Newsroom-06

US Appeals Court Finds Creative Compounds Guilty of Trademark Infringement Against Sabinsa’s ForsLean®

  • June 14, 2010
  • .Press Releases
  • .0 Comments
Sabinsa’s International Presence Sabinsa Corporation has achieved a significant victory in protecting its intellectual property investment in ForsLean® w...
Read More
Posted by forslean
  • Share
  • Tweet
Sabinsa Granted Forskolin Solubility Patent In China

Sabinsa Secures International Forskolin Patent: Granted In Republic of South Africa & Singapore

  • September 12, 2008
  • .Press Releases
  • .0 Comments
Sabinsa has been granted a patent in South Africa and Singapore as part of its PCT application on “Process of preparing water soluble diterpenes and their app...
Read More
Posted by forslean
  • Share
  • Tweet
1 2 3

Recent Press Releases

  • ForsLean addresses overall metabolic health and not just weight management, says Mr. Shaheen Majeed, President-Worldwide, Sabinsa

    02 May. 2019
    View Post
  • Sabinsa Awarded New Patents For ForsLean®: New Scientific Discoveries Warrant Energy Balance Claims

    04 April. 2019
    View Post
  • Sabinsa Publishes ForsLean® Safety Data in International Journal of Pharmacy & Pharmaceutical Research

    19 January. 2016
    View Post
  • Sabinsa Introduces Softgel Ready ForsLean® Soft Extracts Amid Exponential Growth In Coleus Demand: Company Cautions Against Low Quality Spam Knockoffs

    08 July. 2014
    View Post
  • Sabinsa Receives Payment from Creative Compounds for ForsLean® Trademark Infringement

    10 July. 2012
    View Post
  • Creative Compounds’ Attempt to Continue Trademark Infringement of Sabinsa’s ForsLean® Rejected by US Supreme Court

    09 February. 2011
    View Post
  • Sabinsa Granted Forskolin Solubility Patent In China

    15 December. 2010
    View Post
  • Sabinsa’s ForsLean® Gets PI Numbers From TGA To Enter Australian Market

    12 July. 2010
    View Post
  • US Appeals Court Finds Creative Compounds Guilty of Trademark Infringement Against Sabinsa’s ForsLean®

    14 June. 2010
    View Post
  • Sabinsa Secures International Forskolin Patent: Granted In Republic of South Africa & Singapore

    12 September. 2008
    View Post
About Sabinsa

Sabinsa is a manufacturer, supplier and marketer of herbal extracts, cosmeceuticals, minerals, dietary supplements and specialty fine chemicals for the nutritional, cosmetic, pharmaceutical and food industries.

Read More...
Headquarters

Sabinsa Corporation

20 Lake Drive 

East Windsor

NJ 08520, USA

Tel : +1 732 777 1111

Fax: +1 732 777 1443

info@sabinsa.com
Global Contact List
USAGermany
Utah, USAIndia
AustraliaJapan
BrasilPoland
CanadaSouth Korea
ChinaSouth Africa
Contact Us

©2021 Sabinsa. All Rights Reserved | Powered by Edkal Technologies | Privacy Policy | Sitemap | Terms of Use | Disclaimer

Disclaimer

US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.